Nymox Pharmaceutical Corp (NYMX) 5.48 $NYMX
Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels
GlobeNewswire - 1 hr 21 mins ago
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new study findings showing that the Company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or 15 mg (n=46) showed no statistically significant change as compared to control active surveillance patients (n=48). This data is consistent with the large body of existing data for men treated with NX-1207 (n over 1,000) showing a favorable sexual profile for the treatment.
Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
GlobeNewswire - Thu May 08, 9:30AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the last enrolled patient has completed participation in the Company's pivotal Phase 3 clinical trial, NX02-0018. The NX02-0018 trial is the second of two pivotal prospective double blind placebo-controlled U.S. clinical trials being conducted to evaluate NX-1207 2.5 mg for the treatment of benign prostatic hyperplasia (BPH), a common affliction of older men. The first pivotal Phase 3 trial of NX-1207 for BPH, NX02-0017, has already completed patient participation. Both trials will be unblinded once data verification and auditing activities have been completed.
Nymox Announces Positive New Prostate Cancer Clinical Trial Results
GlobeNewswire - Tue May 06, 9:16AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results for this trial. A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers. The study found after up to 22 months for NX-1207 single-injection treated patients there was an 85% reduction compared to controls in the proportion of patients who had upgraded blinded biopsy results in the treated area and went on to require and receive radiation therapy and/or prostatectomy (surgery).
Nymox Reports Top-Line Results for Localized Prostate Cancer Study
GlobeNewswire - Wed Apr 30, 8:30AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report top-line results from the company's 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c) prostate cancer treated with a single injection of NX-1207 into the area of the prostate where cancer was found. Consistent with earlier clinical trial experience with NX-1207, there were no significant safety issues or side effects associated with the drug in the new study.
Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f348jl/benign_prostatic) has announced the addition of the "Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - Euroscreen S.A. - Aphios Corporation - Astellas Pharma Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Addex Therapeutics - AEterna Zentaris Inc. - IntelGenx Corp. - Kaken Pharmaceutical Co., Ltd. - Karo Bio AB - Nymox Pharmaceutical Corporation - Quest PharmaTech Inc. - Sophiris Bio, Inc. - AndroScience Corporation - NovaLead Pharma Pvt. Ltd. - AmVac AG - KAEL-GemVax Co., Ltd. - Ausio Pharmaceuticals, LLC - Hanmi Pharmaceuticals, Co. Ltd. - SOM Biotech SL - Curadis GmbH - Balonco GMBH Drug Profiles - tadalafil - NX-1207 - topsalysin - MCS-2 - ozarelix - teverelix - AUS-131 - udenafil - AMV-110 - ASP-4901 - AMV-100 - ASP-0306 - ASP-6432 - CKD-902 - ADX-68692 - Sperol - tertomotide - ASC-JM.X2 - VLDM-01 - ESN-364 - SL-052 - Estrogen Receptor Program - S-40542 - NCE-403 - SOM-2391 - (tamsulosin dutasteride) - CH-5036249 - L1AD3 - Kisspeptin Peptide Antagonists - CR-1493 - SOM-2393 - Small Molecule to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - INT-0031 For more information visit http://www.researchandmarkets.com/research/f3..._prostatic
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
5 Stocks Poised for Breakouts
at The Street - Fri Apr 11, 7:23AM CDT
These stocks look ready to break out and trade higher from current levels.
Nymox Pharmaceutical announces lower net loss of USD4.91m in 2013
M2 - Mon Mar 17, 7:45AM CDT
Therapeutics company Nymox Pharmaceutical (NasdaqCM:NYMX) on Friday declared a net loss of USD4.91m (USD0.14 per share) for the year ended 31 December 2013.
Nymox Reports 2013 Financial Results
GlobeNewswire - Fri Mar 14, 12:00PM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the year ended December 31, 2013, compared to $7,627,589, or $0.23 per share for same period in 2012. The decrease of the net loss for the year is attributable primarily to a reduction of stock-based compensation charges which were $307,326 in 2013 compared to $1,962,085 in 2012. The weighted average number of common shares outstanding for the year ended December 31, 2013 was 34,147,666, compared to 33,176,185 for the same period in 2012.
Nymox Pharmaceutical Corporation names Andre Monette as CFO
M2 - Thu Feb 06, 5:25AM CST
Biopharmaceutical company Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) revealed on Wednesday that it has appointed Andre Monette as its chief financial officer.
Nymox Announces Appointment of Andre Monette
GlobeNewswire - Wed Feb 05, 1:00PM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company. Mr. Monette, who is a Chartered Professional Accountant and Chartered Financial Analyst, brings to the company extensive experience and expertise in the financial and securities sectors as an executive in the securities industry and as a CFO of a public company. Mr. Monette served for seventeen years as Vice President of Finance and Administration for the North American subsidiary of Lombard Odier Group, a private Swiss bank based in Geneva. Prior to joining Nymox he provided corporate consulting services in financial reporting.
Nymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
GlobeNewswire - Tue Jan 28, 10:30AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided updates on pivotal Phase 3 development activities for NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase 2 for localized prostate cancer. The Company's two large pivotal prospective double blind placebo-controlled U.S. clinical trials (NX02-0017 and NX02-0018) have completed enrollment. One open label safety study (NX02-0020) of subjects who have received a second injection of NX-1207 has completed enrollment and 6 month data has been reported previously. A second open label reinjection study (NX02-0022) is in progress. In Europe, patient recruitment is ongoing at investigational sites in five major European countries in a Phase 3 blinded comparator-controlled clinical trial under the sponsorship of the Company's European licensing partner, Recordati S.p.A.
No Plans to Turn Save Valley Conservancy Into National Park
by Alex Bell - All Africa Global Media - Wed Jan 22, 2:12AM CST
Authorities at the Save valley Conservancy have denied claims that plans are underway to turn the area into a national park, after reports quoted the new tourism minister as saying this was in the pipeline.
Nymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial
GlobeNewswire - Mon Jan 13, 9:00AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.
Nymox Reports Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 14, 9:15AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2013. Nymox reported a net loss of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September 30, 2013, compared to $1,245,563, or $0.04 per share, for the quarter and $4,813,666, or $0.15 per share, for the nine months ended September 30, 2012. The decrease in net losses in 2013 compared to 2012 is related to reductions in many areas of expenditures mainly due to a reduction in clinical trial expenditures as the NX-1207 studies near completion.
Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
GlobeNewswire - Mon Nov 11, 10:45AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The most recent Safety Monitoring Committee meeting found no significant safety concerns to date. Enrollment in this study at participating investigational sites across the U.S. has passed the 50% accrual level.
OTC Daily Alert Stock Watch - Nymox Pharmaceutical Corporation, (NASDAQ: NYMX)
WorldStockWire - Wed Sep 11, 9:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Nasdaq stocks posting largest percentage decreases
AP - Mon Sep 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Urinary Tract Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q89r4h/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2013" report to their offering. 'Urinary Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Urinary Tract Infections Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Toyama Chemical Co. Ltd - Paratek Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Plethora Solutions Holdings plc - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - ConjuGon, Inc. - Osel Inc. - Pinnacle Pharmaceuticals, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/q8...nary_tract
Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect Testosterone Levels
GlobeNewswire - 1 hr 21 mins ago
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported today positive new study findings showing that the Company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or 15 mg (n=46) showed no statistically significant change as compared to control active surveillance patients (n=48). This data is consistent with the large body of existing data for men treated with NX-1207 (n over 1,000) showing a favorable sexual profile for the treatment.
Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
GlobeNewswire - Thu May 08, 9:30AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today that the last enrolled patient has completed participation in the Company's pivotal Phase 3 clinical trial, NX02-0018. The NX02-0018 trial is the second of two pivotal prospective double blind placebo-controlled U.S. clinical trials being conducted to evaluate NX-1207 2.5 mg for the treatment of benign prostatic hyperplasia (BPH), a common affliction of older men. The first pivotal Phase 3 trial of NX-1207 for BPH, NX02-0017, has already completed patient participation. Both trials will be unblinded once data verification and auditing activities have been completed.
Nymox Announces Positive New Prostate Cancer Clinical Trial Results
GlobeNewswire - Tue May 06, 9:16AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today new positive outcome results from the Company's ongoing prospective trial of NX-1207 for the treatment of low grade localized prostate cancer. These are the first clinical patient treatment outcome results for this trial. A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers. The study found after up to 22 months for NX-1207 single-injection treated patients there was an 85% reduction compared to controls in the proportion of patients who had upgraded blinded biopsy results in the treated area and went on to require and receive radiation therapy and/or prostatectomy (surgery).
Nymox Reports Top-Line Results for Localized Prostate Cancer Study
GlobeNewswire - Wed Apr 30, 8:30AM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report top-line results from the company's 146 patient NX03-0040 Phase 2 U.S. prostate cancer study. The results from the study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c) prostate cancer treated with a single injection of NX-1207 into the area of the prostate where cancer was found. Consistent with earlier clinical trial experience with NX-1207, there were no significant safety issues or side effects associated with the drug in the new study.
Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f348jl/benign_prostatic) has announced the addition of the "Global Benign Prostatic Hyperplasia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Eli Lilly and Company - Euroscreen S.A. - Aphios Corporation - Astellas Pharma Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Addex Therapeutics - AEterna Zentaris Inc. - IntelGenx Corp. - Kaken Pharmaceutical Co., Ltd. - Karo Bio AB - Nymox Pharmaceutical Corporation - Quest PharmaTech Inc. - Sophiris Bio, Inc. - AndroScience Corporation - NovaLead Pharma Pvt. Ltd. - AmVac AG - KAEL-GemVax Co., Ltd. - Ausio Pharmaceuticals, LLC - Hanmi Pharmaceuticals, Co. Ltd. - SOM Biotech SL - Curadis GmbH - Balonco GMBH Drug Profiles - tadalafil - NX-1207 - topsalysin - MCS-2 - ozarelix - teverelix - AUS-131 - udenafil - AMV-110 - ASP-4901 - AMV-100 - ASP-0306 - ASP-6432 - CKD-902 - ADX-68692 - Sperol - tertomotide - ASC-JM.X2 - VLDM-01 - ESN-364 - SL-052 - Estrogen Receptor Program - S-40542 - NCE-403 - SOM-2391 - (tamsulosin dutasteride) - CH-5036249 - L1AD3 - Kisspeptin Peptide Antagonists - CR-1493 - SOM-2393 - Small Molecule to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - INT-0031 For more information visit http://www.researchandmarkets.com/research/f3..._prostatic
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
5 Stocks Poised for Breakouts
at The Street - Fri Apr 11, 7:23AM CDT
These stocks look ready to break out and trade higher from current levels.
Nymox Pharmaceutical announces lower net loss of USD4.91m in 2013
M2 - Mon Mar 17, 7:45AM CDT
Therapeutics company Nymox Pharmaceutical (NasdaqCM:NYMX) on Friday declared a net loss of USD4.91m (USD0.14 per share) for the year ended 31 December 2013.
Nymox Reports 2013 Financial Results
GlobeNewswire - Fri Mar 14, 12:00PM CDT
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2013 prepared in accordance with International Financial Reporting Standards. Nymox reported a net loss of $4,908,603, or $0.14 per share for the year ended December 31, 2013, compared to $7,627,589, or $0.23 per share for same period in 2012. The decrease of the net loss for the year is attributable primarily to a reduction of stock-based compensation charges which were $307,326 in 2013 compared to $1,962,085 in 2012. The weighted average number of common shares outstanding for the year ended December 31, 2013 was 34,147,666, compared to 33,176,185 for the same period in 2012.
Nymox Pharmaceutical Corporation names Andre Monette as CFO
M2 - Thu Feb 06, 5:25AM CST
Biopharmaceutical company Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) revealed on Wednesday that it has appointed Andre Monette as its chief financial officer.
Nymox Announces Appointment of Andre Monette
GlobeNewswire - Wed Feb 05, 1:00PM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce the appointment of Andre Monette as Chief Financial Officer of the Company. Mr. Monette, who is a Chartered Professional Accountant and Chartered Financial Analyst, brings to the company extensive experience and expertise in the financial and securities sectors as an executive in the securities industry and as a CFO of a public company. Mr. Monette served for seventeen years as Vice President of Finance and Administration for the North American subsidiary of Lombard Odier Group, a private Swiss bank based in Geneva. Prior to joining Nymox he provided corporate consulting services in financial reporting.
Nymox Provides Update on NX-1207 Phase 3 BPH and Phase 2 Prostate Cancer Clinical Trial Activities
GlobeNewswire - Tue Jan 28, 10:30AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today provided updates on pivotal Phase 3 development activities for NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), a common affliction of older men. NX-1207 is also in development in Phase 2 for localized prostate cancer. The Company's two large pivotal prospective double blind placebo-controlled U.S. clinical trials (NX02-0017 and NX02-0018) have completed enrollment. One open label safety study (NX02-0020) of subjects who have received a second injection of NX-1207 has completed enrollment and 6 month data has been reported previously. A second open label reinjection study (NX02-0022) is in progress. In Europe, patient recruitment is ongoing at investigational sites in five major European countries in a Phase 3 blinded comparator-controlled clinical trial under the sponsorship of the Company's European licensing partner, Recordati S.p.A.
No Plans to Turn Save Valley Conservancy Into National Park
by Alex Bell - All Africa Global Media - Wed Jan 22, 2:12AM CST
Authorities at the Save valley Conservancy have denied claims that plans are underway to turn the area into a national park, after reports quoted the new tourism minister as saying this was in the pipeline.
Nymox Closes Recruitment for NX-1207 Phase 2 Prostate Cancer Trial
GlobeNewswire - Mon Jan 13, 9:00AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) today announced that recruitment is being closed for the Company's Phase 2 study of NX-1207 for low risk localized prostate cancer (NX03-0040) and that enrollment will be formally completed shortly. Initial top line study results are expected to be available approximately 6-8 weeks after completion of enrollment.
Nymox Reports Third Quarter 2013 Financial Results
GlobeNewswire - Thu Nov 14, 9:15AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the third quarter of 2013. Nymox reported a net loss of $1,020,387, or $0.03 per share, for the quarter and $3,591,682, or $0.11 per share, for the nine months ended September 30, 2013, compared to $1,245,563, or $0.04 per share, for the quarter and $4,813,666, or $0.15 per share, for the nine months ended September 30, 2012. The decrease in net losses in 2013 compared to 2012 is related to reductions in many areas of expenditures mainly due to a reduction in clinical trial expenditures as the NX-1207 studies near completion.
Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
GlobeNewswire - Mon Nov 11, 10:45AM CST
Nymox Pharmaceutical Corporation (Nasdaq:NYMX) reported a favorable update and recent Safety Monitoring Committee review of safety data for the Company's NX02-0022 reinjection study for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The most recent Safety Monitoring Committee meeting found no significant safety concerns to date. Enrollment in this study at participating investigational sites across the U.S. has passed the 50% accrual level.
OTC Daily Alert Stock Watch - Nymox Pharmaceutical Corporation, (NASDAQ: NYMX)
WorldStockWire - Wed Sep 11, 9:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Nasdaq stocks posting largest percentage decreases
AP - Mon Sep 09, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Urinary Tract Infections - Pipeline Review, H2 2013
M2 - Thu Sep 05, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q89r4h/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2013" report to their offering. 'Urinary Tract Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections.Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Involved in Urinary Tract Infections Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Toyama Chemical Co. Ltd - Paratek Pharmaceuticals, Inc. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Plethora Solutions Holdings plc - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - ConjuGon, Inc. - Osel Inc. - Pinnacle Pharmaceuticals, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/q8...nary_tract
